Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record.

Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study

Zucca, Emanuele, Conconi, Annarita, Laszlo, Daniele, López-Guillermo, Armando, Bouabdallah, Reda, Coiffier, Bertrand, Sebban, Catherine, Jardin, Fabrice, Vitolo, Umberto, Morschhauser, Franck, Pileri, Stefano A., Copie-Bergman, Christiane, Campo, Elias, Jack, Andrew, Floriani, Irene, Johnson, Peter, Martelli, Maurizio, Cavalli, Franco, Martinelli, Giovanni, Thieblemont, Catherine · 2013 · Journal of Clinical Oncology

Abstract

Purpose: Apart from localized gastric disease, there is no consensus on standard initial treatment of mucosa-associated lymphoid tissue lymphoma. The IELSG-19 study (Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma) was launched to compare chlorambucil alone versus chlorambucil plus rituximab in patients not previously given systemic anticancer therapy. Patients and Methods: Patients not responding to or not suitable for local therapy were eligible. In arm A, chlorambucil was given daily 6 mg/m 2 orally (PO) for 6 weeks. Responding patients and those with stable disease continued to be given daily chlorambucil 6 mg/m 2 PO for 14 consecutive days every 28 days for four cycles. In arm B, intravenous rituximab 375 mg/m 2 per day was added on days 1, 8, 15, 22, 56, 84, 112, and 140. After completion of the planned accrual, the protocol was amended to introduce a third arm with rituximab alone. We report the planned final analysis of the first two arms (113 patients in arm A and 114 in arm B). Results: At a median follow-up of 62 months, the 5-year event-free survival (EFS) was significantly better for the patients treated in arm B (68% v 50%; P = .002) who, despite similar overall response rates (90% v 87%), achieved a higher complete remission rate (78% v 65%; P = .025). Progression-free survival was also improved but it did not reach statistical significance (P = .057). Five-year overall survival (OS) was 89% in both arms. Both treatments were well tolerated without unexpected toxicities. Conclusion: Both treatments were active; the better response rate and EFS obtained with the addition of rituximab did not translate into improved OS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.40.6272

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 229

Metadata

Authors
Zucca, E., Conconi, A., Laszlo, D., López-Guillermo, A., Bouabdallah, R., Coiffier, B., Sebban, C., Jardin, F., Vitolo, U., Morschhauser, F., Pileri, S. A., Copie-Bergman, C., Campo, E., Jack, A., Floriani, I., Johnson, P., Martelli, M., Cavalli, F., Martinelli, G., & Thieblemont, C.
Venue
Journal of Clinical Oncology
Published
2013-02-10
Volume
31
Issue
5
Pages
565-572
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2163435946
Cited by
229
References
0
FWCI
22.68
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. https://app.cochat.ai/papers/10.1200/jco.2011.40.6272
The paper
Zucca, E., Conconi, A., Laszlo, D., López-Guillermo, A., Bouabdallah, R., Coiffier, B., Sebban, C., Jardin, F., Vitolo, U., Morschhauser, F., Pileri, S. A., Copie-Bergman, C., Campo, E., Jack, A., Floriani, I., Johnson, P., Martelli, M., Cavalli, F., Martinelli, G., & Thieblemont, C. (2013). Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.40.6272

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.